Aikium

Aikium is an early-stage biotech leveraging a proprietary AI-driven platform, Yotta-ML 2, to design and experimentally screen trillion-protein libraries, targeting intrinsically disordered regions and other traditionally inaccessible disease targets. The company was founded by a team with deep expertise from NVIDIA, Harvard, 10x Genomics, and leading research institutes, aiming to deliver novel protein therapeutics for conditions where current modalities fail. While still in a pre-clinical, platform-building phase, Aikium has set an ambitious goal of developing 100 life-changing therapies within the next decade. Its approach combines generative AI, protein language models, and ultra-high-throughput wet-lab experimentation to create a new standard in protein engineering.

Yotta-ML 2: An integrated AI and synthetic biology platform combining proprietary generative AI/protein language models with a trillion-protein 'Yotta display' screening system for yotta-scale (10^24) protein design and testing.

Aikium operates in the highly competitive AI-driven drug discovery space, competing with public companies like Recursion and Exscientia, and private peers like Generate Biomedicines and Absci. Its claimed differentiation is the unprecedented scale (yotta-level) of its integrated wet-lab/AI loop, specifically targeting disordered protein regions and complex membrane proteins where pure structure-based AI models may struggle.